ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 359-364

  Liem, A H ^a,e   Van De Woestijne, A P ^a,b   Roeters Van Lennep, H W O ^a   Zwinderman, A H ^c   Van Der Steeg, W A ^c   Jukema, J W ^d  

^a Oosterschelde Hospital   (Netherlands)

^b Roosevelt Academy   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Oosterscheldeziekenhuizen ^*  (Netherlands)

Author keywords

Apolipoproteins; Cardiovascular disease; Lipoproteins; Risk prediction

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; ROC CURVE; UNIVARIATE ANALYSIS;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 39749154124     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X253906     Document Type: Article

References (25)

1. Lamarche B, Moorjani S, Lupien PJ, et al. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996;94:273-8
2. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet 2004;364: 937-52
4. Sniderman AD, Furberg CD, Keech A, et al. Apoproteins versus lipids as indices of coronary risk and as targets for statin therapy: analysis of the evidence. Lancet 2003;36:777-80
5. Roeters van Lennep JE, Westerveld HT, Roeters van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000;20:2408-13
6. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Airforce/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84
7. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162-9
8. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188-205
9. Srivastava RAK, Srivastava N. High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Mol Cell Biochem 2000; 209:131-44
10. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988;27:25-9
11. Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005;16: 19-25
12. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39
13. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: results of the Goes extension study. Heart 2005;91:1213-14
14. Ad Hoc Committee on Cerebrovascular Disease. A classification and outline of cerebrovascular diseases II. Stroke 1975;6: 564-616
15. Moise A, Clement B, Ducimetière P, Bourassa MG. Comparison of receiver operating curves derived from the same population: a bootstrapping approach. Comput Biomed Res 1985;18: 125-31
16. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall/CRC Press, 1993
17. Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 2005;96:36-43
18. Barter PJ, Ballantyne CM, Carmena R, et al. Report of the thirty person/ten country panel. ApoB versus cholesterol to estimate cardiovascular risk and to guide therapy. J Intern Med 2006;259:247-58
19. Sniderman AD, St-Pierre A, Cantin B, et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173-7
20. Sniderman AD. How, when and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002;90(Suppl):48-54i
21. Van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640-8
22. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-85
23. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332;1115-24
24. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35
25. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006;259:493-519